Clinical studies Bucharest

Clinica RTC Radiology Therapeutic Center SRL este autorizată pentru desfăşurarea studiilor clinice cu beneficiu terapeutic pentru specialităţile de Oncologie Medicală şi Radioterapie conform autorizaţiei 814/2018.

1. MK-6482-022
A Multicenter, Double-Blind, Randomized Phase III Trial to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Carcinoma (ccRCC) Post Nephrectomy (6482-022).

2. MK 7339 – 012
A phase 3 study of Pembrolizumab (MK-3475) in combination with concurrent chemoradiotherapy followed by Pembrolizumab with or without olaparib vs concurrent chemoradiotherapy followed by Durvalumab in participants with unresectable stage III non-small cell lung cancer, locally advanced (NSCLC).

3. I3Y-MC-JPEG
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Abemaciclib in Combination with Abiraterone Plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer.

4. J2J-MC-JZLH
A randomized, open-label, phase III trial of Imlunestrant vs standard adjuvant endocrine therapy in patients who have received 2 to 5 years of prior adjuvant endocrine therapy for ER+, HER2- early breast cancer at high risk of recurrence.

5. AbbVie -M18-868
Phase III, Open-Label, Randomized Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with EGFR Wild-Type and c-Met Overexpression in Locally Advanced Non-Small Cell Non-Squamous Lung Cancer / previously metastatic.

6. R3767-ONC-2011
A Phase 3 Study of Fianlimab (REGN3767, Anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic
Melanoma.

7. Sanofi – EFC15858
Randomized, Open-Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non-Squamous Non-Squamous Lung Cancer Patients with CEACAM5-Positive Tumors.

8. ATLAS – 56021927PCR3003
A randomized, double-blind, placebo-controlled phase 3 study of JNJ-56021927 in subjects with high-risk, localized or locally advanced prostate cancer receiving primary radiotherapy.

1. MK-3475-671
A randomized, double-blind, phase III trial evaluating dual platinum-based chemotherapy +/- pembrolizumab (MK-3475) as neoadjuvant/adjuvant therapy in subjects diagnosed with non-small cell lung cancer (NSCLC, non- small cell lung cancer) operable in stage IIB or IIIA (KEYNOTE-671).

2. I3Y-MC-JPCF
Randomized Phase III Study of Abemaciclib in Combination with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy in Patients with High-Risk, Nodal, Hormone Receptor-High (HR+), Epidermal Growth Factor Early Breast Neoplasm receptor 2 negative (HER-2 negative) – monarchE: I3Y-MC-JPCF.

3. I3Y-MC-JPCM
Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Abiraterone Acetate in Combination with Prednisone, Administered with or Without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer.

4. ZEST – 213831
A randomized, double-blind, phase 3 study comparing the efficacy and safety of Niraparib to placebo in participants with HER 2-negative BRCA mutated or triple-negative breast cancer with molecular disease based on the presence of circulating tumor DNA after definitive therapy (ZEST ).

5. GlaxoSmithKline – 205801
Phase II study to study novel treatment regimens compared with standard treatment in non-small cell lung cancer.

6. GlaxoSmithKline – 209229
Randomized, Double-Blind, Adaptive Design Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of Patients with Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma, PD-L1 positive.

7. GlaxoSmithKline – 205801
Phase II study to study novel treatment regimens compared with standard treatment in non-small cell lung cancer.

8. GlaxoSmithKline – 209227
A randomized, double-blind, adaptive, phase II/III study of GSK3359609 in combination with Pembrolizumab and 5FU-Platinum chemotherapy versus placebo in combination with Pembrolizumab plus 5FU-Platinum chemotherapy for the first-line treatment of recurrent/metastatic squamous cell carcinoma of head and neck.

Dr. Ciubotaru Elena – primary medical oncology doctor

Amethyst Clinic Bucharest

Contact person: Raducanu (Mitca) Iuliana-Andreea